| Product Code: ETC9939351 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Blockbuster Oncology Brands Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Blockbuster Oncology Brands Market - Industry Life Cycle |
3.4 United Kingdom (UK) Blockbuster Oncology Brands Market - Porter's Five Forces |
3.5 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume Share, By Brands, 2021 & 2031F |
3.6 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 United Kingdom (UK) Blockbuster Oncology Brands Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in the UK |
4.2.2 Technological advancements in oncology treatments |
4.2.3 Rising investments in research and development for oncology drugs |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for approval of oncology drugs |
4.3.2 High cost associated with blockbuster oncology brands |
4.3.3 Growing competition from biosimilars and generics |
5 United Kingdom (UK) Blockbuster Oncology Brands Market Trends |
6 United Kingdom (UK) Blockbuster Oncology Brands Market, By Types |
6.1 United Kingdom (UK) Blockbuster Oncology Brands Market, By Brands |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Brands, 2021- 2031F |
6.1.3 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Opdivo, 2021- 2031F |
6.1.4 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Keytruda, 2021- 2031F |
6.1.5 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Perjeta, 2021- 2031F |
6.1.6 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Ibrance, 2021- 2031F |
6.1.7 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Tecentriq, 2021- 2031F |
6.1.8 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Gazyva, 2021- 2031F |
6.1.9 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Darzalex, 2021- 2031F |
6.1.10 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Darzalex, 2021- 2031F |
6.2 United Kingdom (UK) Blockbuster Oncology Brands Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Lung cancer, 2021- 2031F |
6.2.3 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Breast cancer, 2021- 2031F |
6.2.4 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Multiple myeloma, 2021- 2031F |
6.2.5 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Lymphoma, 2021- 2031F |
6.2.6 United Kingdom (UK) Blockbuster Oncology Brands Market Revenues & Volume, By Others, 2021- 2031F |
7 United Kingdom (UK) Blockbuster Oncology Brands Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Blockbuster Oncology Brands Market Export to Major Countries |
7.2 United Kingdom (UK) Blockbuster Oncology Brands Market Imports from Major Countries |
8 United Kingdom (UK) Blockbuster Oncology Brands Market Key Performance Indicators |
8.1 Patient survival rates post-treatment |
8.2 Adoption rate of novel oncology therapies |
8.3 Number of clinical trials conducted for oncology drugs |
8.4 Market penetration of blockbuster oncology brands |
8.5 Patient satisfaction and quality of life improvements post-treatment |
9 United Kingdom (UK) Blockbuster Oncology Brands Market - Opportunity Assessment |
9.1 United Kingdom (UK) Blockbuster Oncology Brands Market Opportunity Assessment, By Brands, 2021 & 2031F |
9.2 United Kingdom (UK) Blockbuster Oncology Brands Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 United Kingdom (UK) Blockbuster Oncology Brands Market - Competitive Landscape |
10.1 United Kingdom (UK) Blockbuster Oncology Brands Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Blockbuster Oncology Brands Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here